These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 19764131)

  • 1. Letter regarding levosimendan in a rat model of severe verapamil poisoning.
    Graudins A
    J Med Toxicol; 2009 Sep; 5(3):175; author reply 176. PubMed ID: 19764131
    [No Abstract]   [Full Text] [Related]  

  • 2. Levosimendan does not improve survival time in a rat model of verapamil toxicity.
    Abraham MK; Scott SB; Meltzer A; Barrueto F
    J Med Toxicol; 2009 Mar; 5(1):3-7. PubMed ID: 19191208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan in regional myocardial ischemia.
    Pieske B
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):379-81. PubMed ID: 12656119
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative hemodynamic effects of levosimendan alone and in conjunction with 4-aminopyridine or calcium chloride in a rodent model of severe verapamil poisoning.
    Graudins A; Wong KK
    J Med Toxicol; 2010 Jun; 6(2):85-93. PubMed ID: 20473651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical properties of OR-1259--a positive inotropic and vasodilatory compound with an antiarrhythmic effect.
    Raasmaja A; Talo A; Haikala H; Nissinen E; Lindén IB; Pohto P
    Adv Exp Med Biol; 1992; 311():423. PubMed ID: 1529781
    [No Abstract]   [Full Text] [Related]  

  • 6. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs.
    Harkin CP; Pagel PS; Tessmer JP; Warltier DC
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):179-88. PubMed ID: 7475041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levosimendan, a new inotropic and vasodilator agent.
    Toller WG; Stranz C
    Anesthesiology; 2006 Mar; 104(3):556-69. PubMed ID: 16508404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan use in several scenarios of acute heart failure.
    Tavares M; Andrade AC; Mebazaa A
    Arq Bras Cardiol; 2008 Mar; 90(3):211-5. PubMed ID: 18392402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan attenuates pulmonary vascular remodeling.
    Revermann M; Schloss M; Mieth A; Babelova A; Schröder K; Neofitidou S; Buerkl J; Kirschning T; Schermuly RT; Hofstetter C; Brandes RP
    Intensive Care Med; 2011 Aug; 37(8):1368-77. PubMed ID: 21626431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts.
    Rump AF; Acar D; Rösen R; Klaus W
    Pharmacol Toxicol; 1994; 74(4-5):244-8. PubMed ID: 8090694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracoronary levosimendan enhances contractile function of stunned myocardium.
    Jamali IN; Kersten JR; Pagel PS; Hettrick DA; Warltier DC
    Anesth Analg; 1997 Jul; 85(1):23-9. PubMed ID: 9212117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.
    Udvary E; Papp JG; Végh A
    Br J Pharmacol; 1995 Feb; 114(3):656-61. PubMed ID: 7735692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs.
    Schwarte LA; Picker O; Bornstein SR; Fournell A; Scheeren TW
    Crit Care Med; 2005 Jan; 33(1):135-42; discussion 246-7. PubMed ID: 15644660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled levosimendan reduces mortality and release of proinflammatory mediators in a rat model of experimental ventilator-induced lung injury.
    Boost KA; Hoegl S; Dolfen A; Czerwonka H; Scheiermann P; Zwissler B; Hofstetter C
    Crit Care Med; 2008 Jun; 36(6):1873-9. PubMed ID: 18496375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Levosimendan].
    Michels G; Herzig S; Hoppe UC
    Dtsch Med Wochenschr; 2005 Oct; 130(43):2444-6. PubMed ID: 16240243
    [No Abstract]   [Full Text] [Related]  

  • 16. Levosimendan and plasma BNP levels: do inflammatory cytokines regulate BNP in chronic decompensated heart failure?
    McLachlan CS; Mossop P
    Eur J Heart Fail; 2006 Mar; 8(2):216-7; author reply 218. PubMed ID: 16488367
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers.
    Lilleberg J; Antila S; Karlsson M; Nieminen MS; Pentkäinen PJ
    Clin Pharmacol Ther; 1994 Nov; 56(5):554-63. PubMed ID: 7955820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
    Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
    Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig.
    Grossini E; Caimmi PP; Molinari C; Teodori G; Vacca G
    J Cardiovasc Pharmacol; 2005 Sep; 46(3):333-42. PubMed ID: 16116339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium sensitizing in sepsis: is levosimendan on the right path?
    Morelli A; Ertmer C; Westphal M
    Crit Care Med; 2008 Jun; 36(6):1981-2. PubMed ID: 18520666
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.